|
GB9301000D0
(en)
*
|
1993-01-20 |
1993-03-10 |
Glaxo Group Ltd |
Chemical compounds
|
|
US6316423B1
(en)
|
1996-04-10 |
2001-11-13 |
The United States Of America As Represented By The Departmant Of Health And Human Services |
Method of treating ischemic, hypoxic and anoxic brain damage
|
|
GB9610031D0
(en)
*
|
1996-05-14 |
1996-07-17 |
Glaxo Group Ltd |
Chemical compounds
|
|
US5888532A
(en)
*
|
1996-08-16 |
1999-03-30 |
Pritsos; Chris A. |
Treatment of alcoholism and related disorders with (nicotinamide-adenine dinucleotide) phosphate derivatives
|
|
TW528755B
(en)
|
1996-12-24 |
2003-04-21 |
Glaxo Group Ltd |
2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives
|
|
EP1014995A4
(de)
|
1997-06-18 |
2005-02-16 |
Aderis Pharmaceuticals Inc |
Zusammensetzungen und verfahren zur verhütung von restenosis nach wiedergefässbildung
|
|
US6110902A
(en)
*
|
1997-06-23 |
2000-08-29 |
Moehler; Hanns |
Method for the inhibition of neuronal activity leading to a focal epileptic seizure by local delivery of adenosine
|
|
YU44900A
(sh)
|
1998-01-31 |
2003-01-31 |
Glaxo Group Limited |
Derivati 2-(purin-9-il)tetrahidrofuran-3,4-diola
|
|
US20020058669A1
(en)
*
|
1998-06-15 |
2002-05-16 |
Herman H. P. M. Van Helden |
Process for the treatment of organophosphate poisoning
|
|
JP3933870B2
(ja)
|
1998-06-23 |
2007-06-20 |
グラクソ グループ リミテッド |
２−（プリン−９−イル）−テトラヒドロフラン−３，４−ジオール誘導体
|
|
US6376521B1
(en)
|
1998-07-10 |
2002-04-23 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
A3 adenosine receptor antagonists
|
|
US6576619B2
(en)
*
|
1999-05-24 |
2003-06-10 |
Cv Therapeutics, Inc. |
Orally active A1 adenosine receptor agonists
|
|
IL133680A0
(en)
*
|
1999-09-10 |
2001-04-30 |
Can Fite Technologies Ltd |
Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist
|
|
CO5180581A1
(es)
*
|
1999-09-30 |
2002-07-30 |
Pfizer Prod Inc |
Compuestos para el tratamiento de la isquemia ciones farmaceuticas que los contienen para el tratamiento de la isquemia
|
|
US6803457B1
(en)
|
1999-09-30 |
2004-10-12 |
Pfizer, Inc. |
Compounds for the treatment of ischemia
|
|
CA2397366C
(en)
|
2000-01-14 |
2011-03-15 |
The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services |
Methanocarba cycloalkyl nucleoside analogues
|
|
US20010051348A1
(en)
|
2000-01-28 |
2001-12-13 |
Lee Chee Wee |
Novel ligands and methods for preparing same
|
|
DE60203702T2
(de)
*
|
2001-01-16 |
2006-03-02 |
Can-Fite Biopharma Ltd. |
Verwendung eines adenosin-a3-rezeptor-agonisten zur hemmung der virenreplikation
|
|
US20020115635A1
(en)
*
|
2001-02-21 |
2002-08-22 |
Pnina Fishman |
Modulation of GSK-3beta activity and its different uses
|
|
EP1241176A1
(de)
*
|
2001-03-16 |
2002-09-18 |
Pfizer Products Inc. |
Purinderivate zur Behandlung von Ischämie
|
|
JP2002338593A
(ja)
*
|
2001-05-22 |
2002-11-27 |
Ajinomoto Co Inc |
β−Ｄ−リボフラノース誘導体又はその光学異性体の製造方法
|
|
US6921594B2
(en)
*
|
2001-12-19 |
2005-07-26 |
Sud-Chemie Inc. |
Exhaust treatment and filtration system for molten carbonate fuel cells
|
|
US6846988B2
(en)
*
|
2002-01-18 |
2005-01-25 |
Adc Telecommunications, Inc. |
Triaxial connector including cable clamp
|
|
US7414036B2
(en)
|
2002-01-25 |
2008-08-19 |
Muscagen Limited |
Compounds useful as A3 adenosine receptor agonists
|
|
WO2004045627A1
(en)
*
|
2002-11-19 |
2004-06-03 |
Can-Fite Biopharma Ltd. |
A3ar agonists for the treatment of inflammatory arthritis
|
|
CZ294538B6
(cs)
*
|
2002-12-30 |
2005-01-12 |
Ústav Experimentální Botaniky Akademie Vědčeské Re |
Substituční deriváty N6-benzyladenosinu, způsob jejich přípravy, jejich použití pro přípravu léčiv, kosmetických přípravků a růstových regulátorů, farmaceutické přípravky, kosmetické přípravky a růstové regulátory tyto sloučeniny obsahující
|
|
US20050101560A1
(en)
*
|
2003-11-12 |
2005-05-12 |
Can-Fite Biopharma Ltd. |
Method of treating an individual with methyl 1-[N6-(3-iodobenzyl)-adenin-9-yl] beta-D-ibofuronamide
|
|
DE602004006895T2
(de)
*
|
2003-12-29 |
2008-01-31 |
Can-Fite Biopharma Ltd. |
Verfahren zur behandlung von multipler sklerose
|
|
AR049384A1
(es)
|
2004-05-24 |
2006-07-26 |
Glaxo Group Ltd |
Derivados de purina
|
|
ME01072B
(de)
|
2004-05-26 |
2012-10-20 |
Inotek Pharmaceuticals Corp |
Purinderivate als adenosin a 1 rezeptoragonisten und anwendungsverfahren dafür
|
|
US7825102B2
(en)
*
|
2004-07-28 |
2010-11-02 |
Can-Fite Biopharma Ltd. |
Treatment of dry eye conditions
|
|
JP4642847B2
(ja)
*
|
2004-07-28 |
2011-03-02 |
キャン−ファイト・バイオファーマ・リミテッド |
シェーグレン症候群を含むドライアイ疾患治療用アデノシンａ３レセプターアゴニスト
|
|
BRPI0515030A
(pt)
*
|
2004-09-09 |
2008-07-01 |
Us Gov Health & Human Serv |
derivados de purina como agonistas de receptor de adenosina a3 e a1
|
|
MX2007003271A
(es)
|
2004-09-20 |
2007-06-05 |
Inotek Pharmaceuticals Corp |
Derivados de purina y metodos de uso de los mismos.
|
|
US20080051364A1
(en)
*
|
2004-11-08 |
2008-02-28 |
Pninna Fishman |
Therapeutic Treatment of Accelerated Bone Resorption
|
|
US20080070860A1
(en)
*
|
2005-02-04 |
2008-03-20 |
Uti Limited Partnership |
Adenosine Analogs Useful as Anti-Bacterial and Anti Protozoan Agents
|
|
GB0514809D0
(en)
|
2005-07-19 |
2005-08-24 |
Glaxo Group Ltd |
Compounds
|
|
EA015683B1
(ru)
|
2005-11-30 |
2011-10-31 |
Инотек Фармасьютикалз Корпорейшн |
Производные пурина и способы их применения
|
|
CA2622879C
(en)
*
|
2005-11-30 |
2011-07-05 |
Can-Fite Biopharma Ltd. |
Use of a3 adenosine receptor agonist in osteoarthritis treatment
|
|
TW200806667A
(en)
*
|
2006-04-13 |
2008-02-01 |
Astrazeneca Ab |
New compounds
|
|
WO2007120097A1
(en)
*
|
2006-04-13 |
2007-10-25 |
Astrazeneca Ab |
Thioxanthine derivatives and their use as inhibitors of mpo
|
|
US7893227B2
(en)
*
|
2006-12-05 |
2011-02-22 |
Lasergen, Inc. |
3′-OH unblocked nucleotides and nucleosides base modified with non-cleavable, terminating groups and methods for their use in DNA sequencing
|
|
US7897737B2
(en)
|
2006-12-05 |
2011-03-01 |
Lasergen, Inc. |
3′-OH unblocked, nucleotides and nucleosides, base modified with photocleavable, terminating groups and methods for their use in DNA sequencing
|
|
PL2137202T3
(pl)
*
|
2007-03-14 |
2017-12-29 |
Can-Fite Biopharma Ltd. |
Sposób syntezy IB-MECA
|
|
AU2008270735C1
(en)
|
2007-06-29 |
2014-03-06 |
Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services |
Dendrimer conjugates of agonists and antagonists of the GPCR superfamily
|
|
EP2227234B1
(de)
*
|
2007-10-15 |
2014-05-07 |
Can-Fite Biopharma Ltd. |
Verfahren zur herbeiführung einer hepatozytenproliferation und seine anwendungen
|
|
US8916570B2
(en)
|
2008-03-31 |
2014-12-23 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
A3 adenosine receptor agonists and antagonists
|
|
CA2720037C
(en)
|
2008-03-31 |
2016-08-23 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Purine derivatives as a3 adenosine receptor-selective agonists
|
|
NZ594812A
(en)
|
2008-06-11 |
2012-12-21 |
Lasergen Inc |
Nucleotides and nucleosides and methods for their use in dna sequencing
|
|
US9181253B2
(en)
|
2008-08-01 |
2015-11-10 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Adenosine receptor agonists, partial agonists, and antagonists
|
|
US8796291B2
(en)
*
|
2008-08-01 |
2014-08-05 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
A3 adenosine receptor antagonists and partial agonists
|
|
CN102427819A
(zh)
|
2009-05-17 |
2012-04-25 |
坎-菲特生物药物有限公司 |
用于减小眼内压的a3腺苷受体激动剂
|
|
EP2456419B1
(de)
|
2009-07-21 |
2016-11-23 |
Oradin Pharmaceutical Ltd. |
A3 adenosine rezeptor liganden zur modulation der pigmentierung
|
|
EP2507241A1
(de)
|
2009-12-02 |
2012-10-10 |
The U.S.A. As Represented By The Secretary, Department Of Health And Human Services |
Methanocarba adenosin-derivate und dendrimerkonjugate daraus
|
|
EP2523669B1
(de)
|
2010-01-11 |
2016-12-07 |
Inotek Pharmaceuticals Corporation |
Kombination, kit und verfahren zur reduzierung des augeninnendrucks
|
|
WO2011107981A1
(en)
|
2010-03-03 |
2011-09-09 |
Government Of The Usa, Represented By The Secretary, Department Of Health And Human Services |
A3ar agonists for the treatment of uveitis
|
|
WO2011119969A1
(en)
|
2010-03-26 |
2011-09-29 |
Inotek Pharmaceuticals Corporation |
Method of reducing intraocular pressure in humans using n6 -cyclopentyladenosine (cpa), cpa derivatives or prodrugs thereof
|
|
US20130109645A1
(en)
|
2010-03-31 |
2013-05-02 |
The united States of America,as represented by Secretary,Dept.,of Health and Human Services |
Adenosine receptor agonists for the treatment and prevention of vascular or joint capsule calcification disorders
|
|
US20130165399A1
(en)
|
2010-06-18 |
2013-06-27 |
Hayashibara Co., Ltd. |
Therapeutic agent for inflammatory diseases, containing adenosine n1-oxide as an effective ingredient
|
|
US9493502B2
(en)
|
2011-01-26 |
2016-11-15 |
Beijing Kbd Pharmaceuticals Co., Ltd. |
Ribofuranosyl purine compounds, methods for preparing the same and use thereof
|
|
CN102617680B
(zh)
*
|
2011-02-01 |
2014-04-02 |
复旦大学 |
一种双功能抗血小板聚集药物及其用途
|
|
DE102011005232A1
(de)
|
2011-03-08 |
2012-09-13 |
AristoCon GmbH & Co. KG |
Adenosin und seine Derivate zur Verwendung in der Schmerztherapie
|
|
MX342195B
(es)
|
2011-09-13 |
2016-09-20 |
Lasergen Inc |
Nucleótidos de terminación de rápida fotodescomposición 5-metoxi, 3' -oh no bloqueados y métodos para secuenciación de ácido nucleico.
|
|
PT2807178T
(pt)
|
2012-01-26 |
2017-08-08 |
Inotek Pharmaceuticals Corp |
Polimorfos anidros de nitrato de (2r,3s,4r,5r)-5-(6-(ciclopentilamino)-9h-purin-9-il)-3,4-dihidroxitetrahidrofuran-2-il)}metilo e seus processos de preparação
|
|
CN103421067A
(zh)
*
|
2012-05-18 |
2013-12-04 |
复旦大学 |
一种双靶点抗血小板聚集药物及其用途
|
|
EP2892533A1
(de)
|
2012-08-09 |
2015-07-15 |
Can-Fite Biopharma Ltd. |
A3-adenosinrezeptorliganden zur verwendung bei der behandlung von sexueller dysfunktion
|
|
JP2016513706A
(ja)
|
2013-03-15 |
2016-05-16 |
イノテック ファーマシューティカルズ コーポレイション |
点眼用製剤
|
|
JP2015172077A
(ja)
*
|
2015-06-24 |
2015-10-01 |
中国医学科学院葯物研究所 |
Ｎ６−置換アデノシン誘導体とｎ６−置換アデニン誘導体の鎮静、催眠、抗うつ、抗痙攣、抗てんかん、抗パーキンソン病と認知証予防・治療の用途
|
|
IL242723B
(en)
|
2015-11-23 |
2019-12-31 |
Can Fite Biopharma Ltd |
A3 adenosine receptor ligand for the treatment of ectopic fat accumulation
|
|
CN114903903A
(zh)
*
|
2016-04-21 |
2022-08-16 |
阿斯特罗赛特制药公司 |
治疗神经和心血管病况的化合物和方法
|
|
CN106632333A
(zh)
*
|
2016-11-30 |
2017-05-10 |
湖州恒远生物化学技术有限公司 |
一种低成本8‑氯茶碱的制备方法
|
|
IL254535A0
(en)
|
2017-09-17 |
2017-11-30 |
Can Fite Biopharma Ltd |
Adenosine a3 receptor ligand for use in the management of cytokine release syndrome
|
|
CN109666053A
(zh)
*
|
2017-10-16 |
2019-04-23 |
张家口华健致远生物科技有限公司 |
一种a3腺苷受体激动剂及其用途
|
|
WO2019105388A1
(zh)
*
|
2017-11-29 |
2019-06-06 |
苏州科睿思制药有限公司 |
一种a3腺苷受体激动剂药物的晶型及其制备方法和用途
|
|
US11839615B2
(en)
|
2018-02-09 |
2023-12-12 |
Astrocyte Pharmaceuticals, Inc. |
Compounds and methods for treating addiction and related disorders
|
|
CA3113250A1
(en)
|
2018-09-26 |
2020-04-02 |
Astrocyte Pharmaceuticals, Inc. |
Polymorphic compounds and uses thereof
|
|
IL264112A
(en)
|
2019-01-06 |
2020-07-30 |
Fishman Pnina |
Adenosine a3 receptor ligand for use in lowering adipocyte levels
|
|
WO2022143740A1
(zh)
*
|
2020-12-29 |
2022-07-07 |
浙江春禾医药科技有限公司 |
A3腺苷受体激动剂及其制备方法和用途
|
|
IT202300014340A1
(it)
|
2023-07-10 |
2025-01-10 |
Consiglio Nazionale Ricerche |
Trattamento di malattie associate alla disfunzione del gene ocrl.
|
|
IT202300020286A1
(it)
|
2023-10-02 |
2025-04-02 |
Procos Spa |
Processo per la sintesi di piclidenoson a partire dall’adenosina
|